PMCPA Case Library

1,752 PMCPA Rulings.
Every One Analysed.

The only structured, searchable PMCPA case library in the UK. Expert video walkthroughs, podcast episodes, and MCQ assessments on every ruling — so you understand why companies breach the Code, not just that they did.

▶ Video analysis per case
🎧 Podcast per case
✍ MCQ + CPD certificate
🔒 From £299/year
1752+
Case Studies
5 min
Per Video
5 pts
Per Case Passed
8
Themes
📚
Subscribe for full case library access
Read free summaries below, or subscribe to unlock expert video walkthroughs, podcast audio and CPD certificates.
Sign in See plans ↓
Free — Browsing
✓ Browse all 1752+ case titles
✓ Filter by theme & therapy area
✓ See case reference, company & outcome
✗ Search by company or clause
✗ Video walkthroughs
✗ Podcast episodes
✗ MCQ assessments & CPD certificates
Subscribed — Full Access
✓ Search by company, clause & case ref
✓ Expert video walkthrough per case
✓ Podcast episode per case
✓ MCQ quiz — 5 CPD points per pass
✓ Personalised CPD completion certificate
✓ New cases added monthly
Subscribe from £299/year →
Search by company, clause, case reference... 🔒
All (1752) Social Media & Digital (720) HCP Hospitality & Meetings (431) Data & Publications (321) Off-label Promotion (219) Patient Organisations (44) Transfers of Value (9) Promotional Material (4) Samples & Gifts (2)
Therapy Area: All areas Other (360) Oncology (218) Cardiovascular (189) Respiratory (178) CNS & Neurology (169) Infectious Diseases (115) Diabetes (114) Rare Diseases (104) Immunology & Rheumatology (84) Dermatology (67) Obesity & Weight Management (63) Musculoskeletal & Bone (60) Ophthalmology (31)
Showing 30 results · Data & Publications · Diabetes  · Clear
🔒 Subscribers only
AUTH/3454/1/21
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
An anonymous, non-contactable complainant (describing themselves as a Sanofi representative) raised concerns about briefing materials for Toujeo Coach, a patient support programme for adults prescr…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3560/9/21
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Anonymous health professional complaint about pressure to sign up to diabetes review service (No bre
An anonymous, non-contactable complainant (describing themself as a nurse) alleged a named Sanofi diabetes representative (account executive) repeatedly asked them to sign up to a diabetes review s…
Clauses: NONE
2021 🔒 Subscribe
🔒 Subscribers only
AUTH/3125/11/18
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Takeda v Merck Sharp & Dohme
Takeda (Vipidia/alogliptin) raised inter-company dialogue with Merck Sharp & Dohme (Januvia/sitagliptin) about a “Sitagliptin Information Pack” that mentioned alogliptin and displayed the i…
2018 🔒 Subscribe
🔒 Subscribers only
AUTH/2938/2/17
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi v Novo Nordisk
Sanofi UK complained about a Novo Nordisk promotional leavepiece for Tresiba (insulin degludec) (ref UK/TB/1214/0302(4)).Page 3 headline claim: “Tresiba provides 75% less variability in glucose-l…
Clauses: 3.2,4.1,4.2
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2948/3/17
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Novo Nordisk breached ABPI Code over misleading Tresiba cost comparison email (AUTH/2948/3/17)
A general practitioner complained about a promotional email for Tresiba (insulin degludec) sent by Novo Nordisk (ref UK/TB/1116/0498).The email opened with claims including “Get HbA1c DOWN with C…
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2970/8/17
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen promotional email about Invokana rebates
An anonymous, non-contactable complainant raised concerns about a Janssen regional business manager (RBM) and an email promoting/relating to Invokana (canagliflozin) for type 2 diabetes.The complai…
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/3006/12/17
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
PMCPA AUTH/3006/12/17
A complaint was brought by the PMCPA Director against Lilly.The subject matter related to clinical trial disclosure for Trulicity.Complaint received: 20 December 2017.Case completed: 06 March 2018.
Clauses: NONE
2017 🔒 Subscribe
🔒 Subscribers only
AUTH/2896/11/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Janssen
A complaint was considered under case AUTH/2896/11/16.The case related to clinical trial disclosure for Invokana.The complainant was the Director (PMCPA).Company: Janssen.
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2907/11/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Takeda
A matter was considered by the PMCPA involving the Director and Takeda.The case related to clinical trial disclosure for Vipidia.Complaint received: 06 December 2016.
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2855/7/16
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim and Lilly
A pharmacist complained about a promotional email (Ref UK/GLA/00177) sent (5 July 2016) to a nurse in an NHS clinical commissioning group (CCG).The email subject line stated: “Biosimilar insulin …
Clauses: 9.1
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2836/4/16
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AUTH/2836/4/16 AstraZeneca v Janssen
AstraZeneca UK complained about Janssen-Cilag promotional materials for Invokana (canagliflozin): two leavepieces (Oct 2015 PHGB/VOK/0815/0020; Jan 2016 PHGB/VOK/0815/0020(1)) and a journal adverti…
Clauses: NONE
2016 🔒 Subscribe
🔒 Subscribers only
AUTH/2695/1/14
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
A member of the public made a complaint to the PMCPA about clinical trial disclosure relating to Lyxumia.The matter was reviewed under the ABPI Code of Practice (applicable Code year: 2012).
Clauses: NONE
2014 🔒 Subscribe
🔒 Subscribers only
AUTH/2581/2/13
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
MSD’s Januvia leavepiece
Boehringer Ingelheim and Eli Lilly complained about a Merck Sharp & Dohme (MSD) promotional leavepiece for Januvia (sitagliptin) (ref DIAB-1061227), used as a linagliptin rebuttal/objection-han…
Clauses: NONE
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2620/7/13
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi breached an undertaking over a repeat “only once-daily GLP‑1RA” claim in a Nursing Times supp
Novo Nordisk alleged that a claim for Lyxumia (lixisenatide) in a Nursing Times promotional supplement breached an undertaking Sanofi had given in an earlier case (AUTH/2604/5/13).The supplement (p…
Clauses: 2
2013 🔒 Subscribe
🔒 Subscribers only
AUTH/2412/6/11
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Lilly
An anonymous, non-contactable hospital staff member complained that Eli Lilly placed a large number of Byetta (exenatide) samples in the hospital pharmacy to encourage doctors to prescribe.The comp…
Clauses: NONE
2011 🔒 Subscribe
🔒 Subscribers only
AUTH/2445/10/11
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Boehringer Ingelheim
A general practitioner complained about a company-linked (sponsored) article on linagliptin (later marketed as Trajenta) published in Future Prescriber (July/August 2011), before marketing authoris…
Clauses: NONE
2011 🔒 Subscribe
🔒 Subscribers only
AUTH/2440/10/11
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AUTH/2440/10/11 & AUTH/2441/10/11
A general practitioner complained about a UK medical media press release (UK/TRJ/00004e) issued by Boehringer Ingelheim Limited and Eli Lilly and Company Limited at the UK launch of Trajenta (linag…
Clauses: 9.1,12.1
2011 🔒 Subscribe
🔒 Subscribers only
AUTH/2426/8/11
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
AstraZeneca & Bristol-Myers Squibb
Two complaints from members of the public challenged a full-page Onglyza (saxagliptin) advertorial placed in the Health Service Journal (HSJ) (published 4 August 2011).Concerns were that HSJ is rea…
Clauses: NONE
2011 🔒 Subscribe
🔒 Subscribers only
AUTH/2347/8/10
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Bristol
An anonymous, non-contactable GP alleged Bristol-Myers Squibb (BMS) asked its field force to get GPs to prescribe saxagliptin (Onglyza) for a pre-determined number of patients within set time perio…
Clauses: NONE
2010 🔒 Subscribe
🔒 Subscribers only
AUTH/2152/8/08
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
Novo Nordisk complained about a mailer and two leavepieces produced by Sanofi-Aventis promoting Lantus (insulin glargine); Novo Nordisk marketed Levemir (insulin detemir).Mailer (LAN08/1041) used o…
Clauses: NONE
2008 🔒 Subscribe
🔒 Subscribers only
AUTH/2141/7/08
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Sanofi
Novo Nordisk complained about Sanofi-Aventis’ promotion of Lantus (insulin glargine); Novo Nordisk marketed Levemir (insulin detemir).Materials: four leavepieces (LAN07/1333; LAN08/1037; LAN08/10…
Clauses: NONE
2008 🔒 Subscribe
🔒 Subscribers only
AUTH/2184/11/08
Data & Publications Not Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Pfizer
A Primary Care Trust head of medicines management and a GP medical advisor/GP complained about a Pfizer journal advertisement for Lipitor (atorvastatin) placed in Guidelines in Practice (ref LIP305…
Clauses: NONE
2008 🔒 Subscribe
🔒 Subscribers only
AUTH/2071/11/07
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
Takeda UK Limited — Competact (pioglitazone and metformin); Actos (pioglitazone)
A general practitioner complained about a Takeda UK Limited promotional leavepiece (ref AC070946) for Competact (pioglitazone and metformin) and Actos (pioglitazone).The complaint alleged that data…
Clauses: 7.2
2007 🔒 Subscribe
🔒 Subscribers only
AUTH/2012/6/07
Data & Publications Upheld 🏥 Diabetes ▶ Video 🎙 Podcast
GSK v Takeda
GlaxoSmithKline complained about a Takeda mailer for Competact (pioglitazone/metformin) (ref CM060811).The mailer claimed: “Unlike other glitazone combination therapies, Competact costs LESS to p…
Clauses: 3.2
2007 🔒 Subscribe
1 2 Next → Page 1 of 2 — 30 cases
Unlock the Full Case Library
Annual subscription — instant access, cancel anytime.
🏆
The only PMCPA case library of its kind
No other provider publishes a structured, searchable library of PMCPA rulings with video and podcast. A single half-day compliance workshop from a specialist provider typically costs £499+ — for one session. Individual access here is £299 for a full year of 2,000+ cases.
PMCPA Case Library — Team (100 seats)
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
Enquire for bulk pricing →
Individual
For a single learner
£299
per year
Less than a single half-day workshop
  • 1 user seat
  • All 1752+ case studies
  • Video + podcast per case
  • MCQ quiz per case
  • 5 points per case passed
  • New cases added monthly
Create account or sign in to buy
Most Popular
Team 5
Up to 5 team members
£999
per year (£200/seat)
£200/person — the most cost-effective team option
  • 5 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • New cases added monthly
  • Admin management portal
Create account or sign in to buy
Team 25+
25+ team members
Custom pricing
tailored to your team size
Bulk pricing available — contact us for a quote
  • 25 user seats
  • All case studies included
  • Video, podcast & MCQ per case
  • Team progress dashboard
  • Bulk seat management
  • Priority support
Enquire for bulk pricing →

Questions? Email [email protected]  ·  14-day money-back guarantee  ·  Annual subscription, auto-renews